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It has been more than 20 years since Essed and associates
(1) first documented intimal proliferation after percutaneous
transluminal coronary angioplasty (PTCA) as a cause of
restenosis. During this interval, enormous progress has been
made in defining the pathogenetic mechanism of human
restenotic lesions. Today, there is a general consensus that
restenosis involves the interactions of different cytokines,
growth factors, vascular elements, blood cells, and extent of
injury. Based on the experience derived from experimental
models, cell culture, and human pathologic evidence, as well
as angiographic, angioscopic, and intravascular ultrasonog-
raphy observations, the sequence of events that take place in
the artery after stent implantation and that characterize the
restenotic process consists of thrombosis, recruitment of
inflammatory cells, and proliferation/remodeling (2,3). A
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fundamental difference between restenosis occurring after
balloon angioplasty and stenting is that in the latter the
remodeling component is absent and the only component is
hyperplasia as a part of the reparative process to trauma and
as a reaction to the implant of metal (4). As a result of vessel
wall injury, medial smooth muscle cells (SMCs) and adven-
titial myofibroblasts proliferate and migrate into the intimal
layer, resulting in neointimal formation and lumen loss.
Recent reports, however, suggest that SMC proliferation
may not be the key event in lesion formation and that other
cell types may play a more significant role (5). Moreover,
stent-induced appearance of activated platelets, which pro-
motes leukocyte (monocytes and granulocytes) recruitment
to the injured vessel wall and leukocyte-platelet aggregates
in blood, as well as elevated plasmatic levels of monocyte-
related cytokine interleukin-6, has been observed to corre-
late with clinical outcome. In particular, activated mono-
cytes may contribute to neointimal thickening (5) by
generating reactive oxygen species through the production
of growth and chemotactic factors (6), binding to a broad
repertoire of ligands (7), or by matrix metalloprotease
production capable of degrading matrix constituents and
consequently facilitating cell migration (8).
In this issue of the Journal, Fukuda et al. (9) present the
results of a study evaluating the relationship between mono-
cytes and neointimal growth after coronary artery stenting.
The authors divided the patient population into two groups:
with and without in-stent restenosis. In addition, they
evaluated a control group who underwent diagnostic an-
giography without coronary intervention. A total of 107
patients who underwent coronary artery stenting were
studied. Circulating monocyte count was obtained for all
patients daily for seven days. In addition, at six-month
follow-up patients underwent angiographic and volumetric
intravascular analysis. The results are in accordance with
previous observations in animal models with stenting and
with angioplasty alone. Despite the fact that no flow-
cytometric methods have been used to measure early and
late circulating leukocyte activation status, this study clearly
demonstrates that circulating monocytes increase after stent
implantation and the peak monocyte count correlates to the
in-stent neointimal volume. Thus, the authors concluded
that circulating monocytes play a role in the process of
in-stent neointimal hyperplasia.
Indeed, several experimental studies in different animal
models suggest that intimal inflammation is a determinant
of in-stent neointimal growth (10,11). In stented rabbit iliac
arteries, Rogers et al. (12) demonstrated that monocyte
adhesion correlated with neointimal size (r  0.96). A
subsequent study from the same group demonstrated a peak
monocyte adherence to the lumen surface three days after
stenting, which correlated in turn with neointimal forma-
tion (r2  0.916) (13). In porcine injury models, lympho-
histiocytotic cell infiltration around stent struts was associ-
ated with increased neointimal thickness and percent lumen
area stenosis (14). Furthermore, a number of studies dem-
onstrate that the blockade of inflammation and cell adhe-
sion molecules important for neutrophil recruitment atten-
uates neointimal growth (15). M1/70, a CD11b-blocking
monoclonal antibody, was shown to inhibit neutrophil
infiltration and medial SMC proliferation in a balloon
denudation model (16). The blockade of monocyte che-
moattractant protein-1 (MCP-1) and integrins VLA-4
(CD49d/CD29), molecules responsible for monocyte/
macrophage infiltration/activation, attenuated neointimal
formation, and negative remodeling in different animal
models (17–19). Recently, Manka et al. (20) reported in a
carotid artery injury model that apolipoprotein E–deficient
mice with targeted disruption of the P-selectin gene, a
protein stored in the -granules of platelets and Weibel-
Palades bodies of endothelial cell bonding to circulating
monocytes and leukocytes, exhibited dramatic decreases in
monocyte infiltration into the arterial wall, associated with
significant decreases in neointimal hyperplasia (20). Finally,
administration of recombinant human interleukin-10
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(rhuIL-10), an anti-inflammatory cytokine that inhibits
monocytes and macrophage infiltration in hypercholester-
olemic rabbits, resulted in a dramatic reduction in neointi-
mal formation (21).
Can the same evidence be translated into the clinical
arena and related to increased neointimal formation in
patients undergoing percutaneous interventions? Inflamma-
tory cells associated with coronary stent placements in
humans have been described by histomorphometric evalua-
tion in autopsy series both early and long term after stent
placement (22,23). Neutrophils surrounding stent strut
usually are present in the early phase after implant, whereas
macrophages and lymphocytes are seen both in the early and
late phases (24). In addition, the inflammatory response
seems to be related not only to the intensity of injury (25)
but also to the underlying wall morphology: that is, stent
struts in contact with necrotic core or damaged media are
associated with more severe inflammatory cell infiltration
than struts in contact with fibrous plaque. In addition,
chemokines and proinflammatory cytokines that regulate
migration and infiltration of leukocytes at the site of
vascular injury, and subsequently cause leukocyte activation,
have also been demonstrated in humans. In this setting,
up-regulation of Mac-1, a leukocyte integrin (CD11b/
CD18, M2) that promotes adhesion and transmigration
of leukocytes and monocytes, is associated with increased
restenosis in patients subjected to percutaneous revascular-
ization (26–28). Plasma levels of the MCP-1 are signifi-
cantly increased one day after PTCA, and patients with
restenosis had significantly higher MCP-1 levels after
PTCA than those without restenosis (29). Similarly, Hoki-
moto et al. (30) showed significantly higher MCP-1 values
in samples collected 48 h and three months after PTCA in
patients who developed restenosis. These data, along with
the current study, support the view that inflammation plays
a role in neointimal thickening and suggest the validity of
targeting leukocyte recruitment for preventing clinical re-
stenosis.
How can we counteract the adhesion and chemotaxis of
inflammatory leukocytes after stenting when these events
seem to be crucial for the development of restenosis? High
doses of aspirin, the most widely used anti-inflammatory
drug, have been shown to significantly inhibit leukocyte
attack in a three-dimensional human coronary in vitro
model (31) but not in the clinical arena (32,33). Red wine
consumption has been shown to inhibit MCP-1 expression
and reduce the intimal response to injury in animal models
(34). Recently, the Immunosuppressive Therapy for the
Prevention of Restenosis After Coronary Artery Stent
Implantation (IMPRESS) study, in which patients with
persistently high C-reactive protein values (5 mg/dl) who
underwent successful coronary artery implantation had a
54% decrease in in-stent late loss when treated with oral
immunosuppressive prednisone therapy (35). Therefore, it
has been hypothesized that the high systemic inflammatory
response may be due to further activation of the inflamma-
tory process within the plaque itself and to injury during
coronary stenting. On the contrary, other studies examining
the role of systemic corticosteroid administration failed to
show any significant reduction after balloon angioplasty
(36,37). However, in the majority of these studies, cortico-
steroids were used after balloon angioplasty rather than after
stenting, and a single dose was frequently given (38,39).
Most importantly, no attempt has been made to target both
treatment and dosage to patients with high inflammatory
biochemical and cellular markers.
The conflicting results in the field of anti-inflammatory
therapy for the prevention of in-stent hyperplasia may be
due to the fact that the inflammatory component predom-
inates only in some patients. In the present study of Fukuda,
the correlation between the increase in monocyte count and
post-stent hyperplasia had an r value of 0.44, which explains
only part of the problem. In an elegant study, Danenberg et
al. (40) recently demonstrated that the systemic inaction and
depletion of monocytes and macrophages by liposomal
clodronate in animal models reduced neointimal hyperplasia
and restenosis. Along the lines of suppression of monocyte
activation, a recently proposed approach using this concept
will soon be investigated in humans. Nitrogen-containing
bisphosphonates are inhibitors of the mevalonate pathway
and, therefore, block prenylation of small GTPases, such as
Ras, Rho, and Rac. These proteins regulate a variety of cell
processes important for monocyte/macrophage function,
including cell morphology, membrane ruffling, trafficking of
endosomes, and cell survival (41). Once the liposome
containing the bisphosphonate enters the monocyte/
macrophage, the liposome undergoes lipolysis, the drug is
released, and cell activity is halted. Cells that do not possess
the ability to phagocytose are not affected, and a free drug
will either be cleared without cellular absorption or tran-
siently complexed to bone, decreasing systemic toxicity. In
addition, bisphosphonate-loaded liposomes can engage
monocyte/macrophage both locally and systemically, pro-
viding for biological homing of this strategy.
It is worthwhile to note that whatever strategy we may
use, the possibility of either growth rebound of neoin-
timal hyperplasia after therapy cessation or development
of neutralizing antibodies, which may render the anti-
inflammatory strategy ineffective over time, should be taken
into account. The study by Fukuda and his colleagues (9)
indicates that measurements of monocytes may be of assis-
tance in identifying patients who are prone to restenosis
after stenting. A combination of present and future strate-
gies will probably represent the final therapeutic solution to
the problem of neointimal hyperplasia. As Andre Cournard
remarked in his Nobel lecture of December 11, 1956, “The
cardiac catheter was . . . the key in the lock”; perhaps drug-
eluting stents associated with anti-inflammatory strategies
will became a “passe-partout” (master key) in the everyday
struggle to reduce restenosis in interventional cardiology.
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